ストックスクリーナーアプリを入手
3.50
2.19%
0.075
前日終値:
$3.425
開ける：
$3.6
24時間の取引高:
37,097
Relative Volume:
0.11
時価総額：
$2.87M
収益：
-
当期純損益:
$-16.73M
株価収益率:
-0.0104
EPS:
-335.7162
ネットキャッシュフロー:
$-14.29M
1週間 パフォーマンス:
-4.63%
1か月 パフォーマンス:
-20.81%
6か月 パフォーマンス:
+69.08%
1年 パフォーマンス:
-55.04%
1日の値動き範囲:
$3.3873
$3.6052
1週間の範囲:
$3.37
$3.84
52週間の値動き範囲:
$0.4229
$55.00
Genprex Inc Stock (GNPX) Company Profile
Compare GNPX vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
3.50 | 3.24M | 0 | -16.73M | -14.29M | -335.72 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-01-26 | 開始されました | National Securities | Buy |
| 2019-04-29 | 開始されました | Noble Capital Markets | Outperform |
Genprex Inc (GNPX) 最新ニュース
Genprex signs CDMO deal to scale up diabetes gene therapy manufacturing - Minichart
Form 8K Genprex Inc For: 18 August By Investing.com - Investing.com Nigeria
Genprex partners with CDMO for diabetes gene therapy manufacturing By Investing.com - Investing.com Nigeria
Genprex (GNPX) Partners with CDMO to Advance Diabetes Gene Thera - GuruFocus
Genprex partners with CDMO for diabetes gene therapy manufacturing - Investing.com
GenprexTransfers Diabetes Product Manufact - Moomoo
Genprex advances AAV diabetes gene therapy manufacturing - TipRanks
Genpre announces CDMO partnership to scale AAV diabetes gene therapy toward cGMP clinical supply - TradingView
Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy - PR Newswire
GNPX Q1 2026 Earnings: Clinical-Stage Biotech Posts $0.64 Per Share Loss as Pipeline Development ContinuesGuidance Update - vinanet.vn
Genprex, Inc. Q2 2026: Net loss $(4.45M), EPS $(9.40) — 10-Q Summary - TradingView
Genprex (NASDAQ: GNPX) details Q2 loss and cash runway into 2027 - Stock Titan
GNPX|Genprex Inc|Price:4.320|Chg%:-0.550 - TradingKey
Genprex (GNPX) Surges 5% on Renewed Biotech Interest — Key Levels to WatchShort Setup Alerts - vinanet.vn
Genprex Strengthens Intellectual Property Portfolio with Japanese and EU Patents for Reqorsa® Gene Therapy in Combination with Immunotherapies to Treat Cancer (PR Newswire) - Aktiellt
Genprex Inc (STU:2DE1) Stock Earnings Transcripts - GuruFocus
Genprex Inc (STU:2DE1) Stock Price & 30 Year Financial Data - GuruFocus
Genprex Inc (GNPX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Genprex Inc (GNPX) Stock News Today - TradingKey
Genprex (GNPX) Q1 2026 Earnings: Net Loss of $0.64 Per Share Highlights Pre-Revenue Clinical Development Stage - vinanet.vn
Genprex Regains Nasdaq Compliance, Listing Status Secured - The Globe and Mail
Genprex, Inc. (NASDAQ: GNPX) regains Nasdaq minimum bid compliance - Stock Titan
Genprex partners with Roche Diagnostics on biomarker validation for NSCLC - Yahoo Finance
Genprex Announces Collaboration with Roche Diagnostics for Biomarker Assay Validation Studies - Morningstar
Genprex, Roche Partner on NSCLC Biomarker Validation - TipRanks
Genprex Shares Rise After Collaboration With Roche Diagnostics - finance.yahoo.com
GNPX Stock Draws Trader Focus After Wild Price Swing - StocksToTrade
Why is Genprex stock sliding today? By Investing.com - Investing.com Canada
Weekly Recap: Nasdaq exception and Roche Diagnostics TROP2 validation - TradingView
Genprex stock rises on Roche Diagnostics collaboration By Investing.com - Investing.com India
Genprex partners with Roche on lung cancer biomarker studies - Investing.com Nigeria
Genprex partners with Roche on lung cancer biomarker studies By Investing.com - Investing.com Canada
Genprex Granted Nasdaq Listing Exception Amid Compliance Push - The Globe and Mail
Genprex Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq panel grants Genprex (NASDAQ: GNPX) conditional listing reprieve - Stock Titan
Genprex Inc (GNPX) Institutional Confidence - TradingKey
Genprex Inc (GNPX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Genprex Inc (GNPX) Earnings Date & Reports & Earnings News - TradingKey
Genprex Inc (GNPX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
GNPX|Genprex Inc|Price:7.735|Chg%:-0.075 - TradingKey
GNPX|Genprex Inc|Price:4.700|Chg%:+0.230 - TradingKey
Genprex Inc Revenue Breakdown – LSE:0A8I - TradingView
AMD Stock Price Today, Analysis, News and Trading Ideas - Stocktwits
GNPX Q1 2026 Earnings: Pre-Revenue Biotech Reports EPS of -$0.64, Shares Slide 11%Weak Earnings Momentum - vinanet.vn
Gross margin % of Genprex Inc – MUN:2DE1 - TradingView
CapEx per share of Genprex Inc – MUN:2DE1 - TradingView
Dilution adjustment of Genprex Inc – MUN:2DE1 - TradingView
Total debt of Genprex Inc – MUN:2DE1 - TradingView
Total revenue of Genprex Inc – MUN:2DE1 - TradingView
Genprex (GNPX) Virtual Road Show with CEO Rodney Varner Transcript - GuruFocus
Genprex Inc (GNPX) 財務データ
収益
当期純利益
現金流量
EPS
Genprex Inc (GNPX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| LONGNECKER BRENT M | Director |
Apr 14 '26 |
Sale |
1.23 |
8 |
10 |
9,157 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):